Apogee Therapeutics announced a $1.3 billion strategic financing deal with Blackstone Life Sciences to support the Phase 3 development and potential commercialization of Zumilokibart, a treatment for moderate-to-severe atopic dermatitis. The funding includes up to $800 million in synthetic royalty payments and up to $500 million in senior corporate debt, providing Apogee with flexible, non-dilutive capital. This deal, combined with Apogee's existing $1.3 billion cash, positions the company to commercialize Zumilokibart without needing future equity financing. The collaboration marks a significant step toward bringing a potentially transformative therapy to market with differentiated efficacy and dosing benefits.
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
The US will impose a 25% tariff on most imports from Brazil starting July 22, following a yearlong investigation into alleged unfair trade practices by Brazil. The tariffs target issues such as Brazil's demands on US tech firms to remove political co...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
